JP2023539247A - Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用 - Google Patents

Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用 Download PDF

Info

Publication number
JP2023539247A
JP2023539247A JP2023513299A JP2023513299A JP2023539247A JP 2023539247 A JP2023539247 A JP 2023539247A JP 2023513299 A JP2023513299 A JP 2023513299A JP 2023513299 A JP2023513299 A JP 2023513299A JP 2023539247 A JP2023539247 A JP 2023539247A
Authority
JP
Japan
Prior art keywords
feline
viral vector
glp
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539247A5 (cg-RX-API-DMAC7.html
Inventor
ウイルソン,ジェームス・エム
ヒンデラー,クリスチャン
真 堀内
Original Assignee
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア filed Critical ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Publication of JP2023539247A publication Critical patent/JP2023539247A/ja
Publication of JP2023539247A5 publication Critical patent/JP2023539247A5/ja
Priority to JP2026035302A priority Critical patent/JP2026115041A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023513299A 2020-08-24 2021-08-24 Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用 Pending JP2023539247A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026035302A JP2026115041A (ja) 2020-08-24 2026-03-05 Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069492P 2020-08-24 2020-08-24
US63/069,492 2020-08-24
PCT/US2021/047403 WO2022046809A1 (en) 2020-08-24 2021-08-24 Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026035302A Division JP2026115041A (ja) 2020-08-24 2026-03-05 Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用

Publications (2)

Publication Number Publication Date
JP2023539247A true JP2023539247A (ja) 2023-09-13
JP2023539247A5 JP2023539247A5 (cg-RX-API-DMAC7.html) 2024-09-02

Family

ID=80355670

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023513299A Pending JP2023539247A (ja) 2020-08-24 2021-08-24 Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用
JP2026035302A Pending JP2026115041A (ja) 2020-08-24 2026-03-05 Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026035302A Pending JP2026115041A (ja) 2020-08-24 2026-03-05 Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用

Country Status (8)

Country Link
US (1) US20230405150A1 (cg-RX-API-DMAC7.html)
EP (1) EP4199942A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023539247A (cg-RX-API-DMAC7.html)
KR (1) KR20230054419A (cg-RX-API-DMAC7.html)
CN (1) CN116390745A (cg-RX-API-DMAC7.html)
AU (1) AU2021332232A1 (cg-RX-API-DMAC7.html)
CA (1) CA3190396A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022046809A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026039341A1 (en) 2024-08-12 2026-02-19 Akston Biosciences Corporation Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026039359A1 (en) 2024-08-12 2026-02-19 Akston Biosciences Corporation Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026039340A1 (en) 2024-08-12 2026-02-19 Akston Biosciences Corporation Fc fusion protein therapeutics for companion animal obesity and methods of use
CN120005002B (zh) * 2025-04-22 2025-07-25 西宝生物科技(上海)股份有限公司 一种glp-1类似物的生物发酵制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528014A (ja) * 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Glp−1融合タンパク質
JP2018523477A (ja) * 2015-08-06 2018-08-23 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Glp−1及び代謝性疾患を治療するための組成物におけるその使用
WO2019035010A1 (en) * 2017-08-15 2019-02-21 Kindred Biosciences, Inc. IGG VARIANTS FOR VETERINARY USE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833623A1 (en) * 2011-04-20 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
EP3481413A4 (en) * 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2020139984A1 (en) * 2018-12-27 2020-07-02 Kindred Biosciences, Inc. Igg fc variants for veterinary use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528014A (ja) * 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Glp−1融合タンパク質
JP2018523477A (ja) * 2015-08-06 2018-08-23 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Glp−1及び代謝性疾患を治療するための組成物におけるその使用
WO2019035010A1 (en) * 2017-08-15 2019-02-21 Kindred Biosciences, Inc. IGG VARIANTS FOR VETERINARY USE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GILOR CHEN ET AL.: "New approaches to feline diabetes mellitus: Glucagon-like peptide-1 analogs", J FELINE MED SURG, vol. 18, no. 9, JPN6025030176, 2016, pages 733 - 743, ISSN: 0005724861 *
NAMBIAR K. ET AL.: "Transduction evaluation of novel AAV natural isolates in nonhuman primates using a barcoded transgen", SGCT 27TH ANNUAL CONGRESS IN COLLABORATION WITH SETGYC BARCELONA, SPAIN, JPN6025030177, 2019, pages 19 - 002, ISSN: 0005724862 *

Also Published As

Publication number Publication date
CN116390745A (zh) 2023-07-04
AU2021332232A1 (en) 2023-03-23
CA3190396A1 (en) 2022-03-03
JP2026115041A (ja) 2026-07-08
KR20230054419A (ko) 2023-04-24
WO2022046809A1 (en) 2022-03-03
US20230405150A1 (en) 2023-12-21
EP4199942A1 (en) 2023-06-28
EP4199942A4 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
CN108368521A (zh) Glp-1和其在用于治疗代谢疾病的组合物中的用途
US20230405150A1 (en) Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines
JP7840319B2 (ja) Glp-1受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用
US20250171515A1 (en) Aav vectors for delivery of glp-1 receptor agonist fusions
US20250388926A1 (en) Viral vector genome encoding an insulin fusion protein
US20250186613A1 (en) Viral vectors encoding glp-2 receptor agonist fusions and uses thereof in treating short bowel syndrome
US20250186612A1 (en) Viral vectors encoding parathyroid hormone fusions and uses thereof in treating hypoparathyroidism

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250723

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260706

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260715